BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases such as COVID-19, asthma, and psoriasis
Collaboration with Max Planck & UMG
GMP biologics manufacturing facility
Extensive drug development expertise
Top-tier pharma leadership
Recent News
Our Mission: To help build a healthier and happier world by developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.
BiondVax’s assets, capabilities and experience position us well for in-licensing, acquisitions, and joint ventures & rapid clinical development and manufacturing of new therapeutic and prophylactic technologies.
Experience
Vaccine Development
Extensive experience in vaccine development from preclinical through multiple clinical trials
Phase 3 clinical trial for prior influenza vaccine candidate in over 12,400 participants, 105 sites and seven countries was completed on time and on budget in the face of the growing threat of COVID-19
Assets
Leadership, Capital & Manufacturing
Big pharma experienced leadership team including Chairman (Alexion), CEO (Novartis and GSK), Board director (BMS), COO (Novartis)
GMP biologics manufacturing facility in Jerusalem, Israel, with CDMO capabilities
Support from European Investment Bank (EIB) with €24m in non-dilutive financing, the first such agreement with a non-EU company
US publicly traded company on Nasdaq: BVXV
Activities
Pipeline Development
Collaboration with Max Planck Society and University Medical Center Göttingen, Germany for a broad-based strategic collaboration towards a new nanosized antibody (NanoAb) pipeline beginning with COVID-19
Exploring additional alternatives towards development of a diverse and robust multi-asset pipeline